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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most frequent malignancy and the third cause of cancer-related death in the world, 1 Since recent technical improvements in the analytical methods of measuring AFP, AFP-L3 and DCP employing an advanced microfluidics-based separation technology have been developed, 8 the aim of the present study was to evaluate the diagnostic accuracy of AFP, AFP-L3 and DCP alone or in combination and to test GALAD model performance for HCC detection in a cohort of Italian patients.
METHODS

Patients
This single-center cross-sectional study included 98 prospectively enrolled patients (68M, 30F; mean age 62.2 ± 14.1 years) with chronic liver disease (CLD) that underwent US screening for hepatic nodular lesion. Final diagnosis of HCC was established by 4-phase multidetector CT scan or dynamic contrast-enhanced MRI showing arterial hypervascularity and washout in the venous/late phase. 3 The degree of liver disease was classified according to clinical, serological and histological criteria where appropriate. Liver cirrhosis was diagnosed by liver biopsy or by laboratory data and imaging findings (US and transient elastography). 9,10 All patients gave their written informed consent prior to recruitment. The study protocol was conformed to the principles of the Declaration of Helsinky and it was approved by the Institutional Ethics Committee.
Measurements of serological biomarkers
Blood samples were collected from each participant at the time of the scheduled outpatient visit.
Sera were stored at -80°C and subsequently analyzed for the concentration of AFP, AFP-L3 and DCP using an automated immunoassay system assay on the µTASWako i30 immuno-analyzer (Wako Chemicals GmbH, Neuss, Germany). 11,12 Analytical assay sensitivities are 0.3 ng/mL for AFP and 0.1 ng/mL for DCP. AFP-L3 is reportable as ratio to total AFP if both AFP-L1 and AFP-L3 are ≥ 0.3 ng/ml. All measurements were carried out in the same sample and were performed in an outside laboratory blinded to diagnosis and details of the patients' clinical histories.
Statistical analysis
AFP, AFP-L3 and DCP values are expressed in medians and ranges. Kruskal-Wallis test was used to evaluate differences in HCC biomarkers levels among groups, while Fisher's exact test was performed to analyze categorical data. To evaluate diagnostic performance of AFP, AFP-L3 and DCP alone or in combination, area under the curve (AUC), sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) were assessed by using receiver operating characteristic (ROC) curves analysis. A logistic regression analysis was performed to evaluate the association of each biomarker with demographical and clinical factors. A p-value <0.05 was considered statistically significant. All statistical analyses were performed using MedCalc software, version 9.2.1.0. ROC curves were calculated to evaluate diagnostic accuracy for AFP, AFP-L3 and DCP alone or in combination to distinguish CLD from HCC (Figure 2) . AUC values, Se, Sp, PPV, NPV and the corresponding cut-off are reported in Table 3 .
RESULTS
Patient
The GALAD model, including gender, age, AFP-L3, AFP and DCP, was tested on our data set and showed a high diagnostic accuracy for HCC diagnosis (Table 4 ). Furthermore a comparison of the diagnostic performance between each biomarker and the GALAD model was performed. Table 5 .
Differences between AUC values and corresponding statistical significance are reported in
DISCUSSION
In the present study AFP, AFP-L3 and DCP showed significantly different median values between CLD and HCC patients and a high diagnostic performance when used as single biomarker (AUC=0.891, AUC=0.870 and AUC=0.867, respectively), allowing patients correct classification in at least 80% of subjects. Moreover, the combination of the 3 biomarkers significantly improved the diagnostic accuracy (AUC=0.947), enhancing Se in HCC detection (Se=94.3%; 87.6% of patients correctly classified).
AFP in particular, has been widely used as biomarker for HCC though several studies showed a lack of adequate Se and Sp for effective surveillance and diagnosis inasmuch that AASLD guidelines state that surveillance should rely on US examination only, whereas EASL guidelines adopt also AFP for surveillance purposes. 13, 14 In fact, several studies reported Sp values approaching 90% for all 3 biomarkers, but significant lower Se (<50%), in particular for early HCC detection. 15 Ultrasound used as surveillance test showed Se values ranging from 58% to 89%, 16, 17 albeit being less effective for early-stage HCC detection (Se=63%). 13 Conversely, JSH guidelines recommend to conduct surveillance programs using a combination of tumor biomarkers such AFP, AFP-L3 and DCP in addition to US for early HCC detection in patients with hepatitis B and C virus-related CLD. Moreover, the strategy to adopt US and AFP has been shown to be helpful and cost-effective particularly in patients with cirrhosis. 18, 19 It is well known that older age and male gender are important risk factors that correlate with HCC development. 20 These parameters have been included in the GALAD model developed by Johnson et al that showed a higher diagnostic accuracy for HCC detection than the combination of AFP, AFP-L3 and DCP in our cohort of patients (ΔAUC=0.029, p=0.028). Moreover, considering that the majority of HCC patients enrolled in our study were stage 0 (27.8%) or stage A (57.4%) according to BCLC staging system, the performance we observed suggests that this model could be suitable for early HCC detection despite a validation in a larger cohort of patients is required.
A limitation of our study could be the difference in etiology and in cirrhosis prevalence between the CLD and HCC patients group. These features, together with the high occurrence of early stage tumors in the HCC group and with the treatment status of HBV-CLD patients (all under nucleos(t)ide analogue treatment), could explain both the lower median values of AFP, DCP and AFP-L3 and the low cut-off found in these cohort. Even if demographic characteristics were not properly balanced between CLD and HCC patients, when we evaluated whether these differences could impact HCC biomarkers performance, we found no effect.
In conclusion, our data gather further evidence for the use of highly sensitive methods for AFP, AFP-L3 and DCP quantitation for HCC detection. The combination of these biomarkers in addition to state-of-the-art ultrasound imaging may prove more powerful to identify patient at risk of HCC in surveillance protocols. NPV, negative predictive value; PPV, positive predictive value; Se, sensitivity; Sp, specificity. 
